SFTPD-AS1

Across TCGA pan-cancer cohorts, SFTPD-AS1 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of SFTPD-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SFTPD-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types SFTPD-AS1 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, KICH, and LUSC are the cancer types where SFTPD-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SFTPD-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	II,III,IV	−0.031	<.001	10	view →
KICH	Male	All	−0.100	<.001	9	view →
LUSC	Female	All	−0.292	<.001	8	view →
COAD	Female	All	−0.026	<.001	6	view →
LUAD	Female	II,III,IV	−0.322	<.001	5	view →
BRCA	All	III,IV	−0.035	.007	4	view →
UCEC	All	All	−0.076	.009	2	view →
KIRP	All	All	−0.059	.003	2	view →
THCA	Female	All	−0.034	.015	2	view →
STAD	All	IV	−0.023	.002	2	view →
HNSC	Female	All	+0.019	.020	2	view →
ESCA	All	All	−0.105	.034	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

SFTPD-AS1–KIRC

Open the KIRC breakdown →